I-Mab to Participate at the Jefferies Global Healthcare Conference

Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in immunotherapies for cancer treatment, announced its participation in the Jefferies Global Healthcare Conference on June 5, 2024.

Key presenters include CEO Raj Kannan and Interim CMO Louie Naumovski, with the presentation scheduled for 9:30 a.m. EST. The event will feature one-on-one and small group meetings with key management members, including CFO Joe Skelton and Senior Director of Investor Relations Tyler Ehler.

The presentation will be available via webcast on I-Mab's Investor Relations website.

Positive

• I-Mab is presenting at a prominent industry conference, enhancing visibility and investor interest.
• CEO Raj Kannan and top management will engage in one-on-one and small group meetings, potentially fostering new partnerships or investments.
• The webcast availability broadens access to stakeholders unable to attend in person, increasing transparency.

Negative

• No new data or updates on the company's progress or financials were provided in the announcement.
• Investor reaction to the presentation could be negative if the content does not meet expectations.

ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024.

Jefferies Global Healthcare Conference

Presentation Time	Wednesday, June 5 at 9:30 a.m. EST
Presenters	Raj Kannan, CEO; Louie Naumovski, Interim CMO
Webcast link	Here
Meetings	One-on-one and small group meetings: June 5, 2024
Management Participants	Raj Kannan, CEO Joe Skelton, CFO Louie Naumovski, Interim CMO Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab's IR website
at https://ir.i-mabbiopharma.com/

For more information, please contact your Jefferies representative.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit  https://ir.i-mabbiopharma.com/ and follow us on LinkedIn and X.

For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-jefferies-global-healthcare-conference-302150438.html

SOURCE I-Mab Biopharma

FAQ

When is I-Mab presenting at the Jefferies Global Healthcare Conference?

I-Mab is presenting on June 5, 2024, at 9:30 a.m. EST.

Who will present for I-Mab at the Jefferies Global Healthcare Conference?

CEO Raj Kannan and Interim CMO Louie Naumovski will present.

Where can I watch the I-Mab presentation at the Jefferies Global Healthcare Conference?

The presentation will be available via webcast on I-Mab's Investor Relations website.

What is the stock symbol for I-Mab?

The stock symbol for I-Mab is IMAB.

Will I-Mab management participate in meetings during the Jefferies Global Healthcare Conference?

Yes, I-Mab management will hold one-on-one and small group meetings on June 5, 2024.